### PubMed Commons comment #2

[Posted by Daniel MacArthur on June 27, 2016](http://www.ncbi.nlm.nih.gov/pubmed/27253448#cm27253448_16381)

We thank the authors for their reply, and for their comparison of their results with those for the G2019S variant in LRRK2 and its association with Parkinson's disease. As a well-established and well-studied pathogenic variant, LRRK2 G2019S is indeed an excellent example to illustrate two points:

1. **Genuinely pathogenic variants are enriched in cases over controls**. In 23andMe's cohort, the largest dataset for which we were able to find published allele counts, *LRRK2* G2019S has an allele frequency of 0.09% in controls and 1.1% in cases, with an odds ratio of 9.6 [[Do 2011], see [Table S1](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121750/bin/pgen.1002141.s005.pdf)] for allele frequency breakdown by case/control status. Another study of Europeans found an allele frequency of 0.8% in idiopathic PD cases [[Gilks 2005]]. The allele frequency in ExAC is accordingly 10-fold lower, 0.04% overall and 0.06% among non-Finnish Europeans. Among PD cases with a positive family history, the variant exhibits even stronger enrichment, with allele frequencies on the order of a few percent [[Kachergus 2005], [Nichols 2005], [Di Fonzo 2005]]. Results from other populations are in agreement: among North African Arabs and Ashkenazi Jews, the variant has an allele frequency of 0.6 - 1.4% in the general population, but a frequency of 9 - 19% in Parkinson's disease cases [[Lesage 2006], [Ozelius 2006]]. 

2. **Pathogenic variants may be found in ExAC, but at a frequency consistent with disease prevalence, penetrance, and allelic heterogeneity**. Published estimates of lifetime risk of Parkinson's disease range from 3.7% [[Elbaz 2002]] to 6.7% [[Driver 2009]]. *LRRK2* G2019S accounts for ~1% of all cases (as noted above), and is estimated to confer lifetime risk of ~32% [[Ozelius 2006], [Goldwurm 2007]]. From these figures, one can infer that allele frequencies even as high as 6.7% * 1% / 32% = 0.2% (a few times higher than what we see in ExAC) would not be surprising for this variant.

On both accounts, *LRRK2* G2019S stands in contrast to *NR1H3* R415Q. *NR1H3* R415Q does not appear to be enriched in cases over controls, and its allele frequency in ExAC is inconsistent with any but the lowest (<2%) penetrance when one considers that multiple sclerosis is apparently less common than Parkinson's disease, and that this variant is found in only a small minority of cases. This contrast thus simply highlights the inadequacy of the genetic evidence supporting any role of NR1H3 R415Q in the etiology of MS.

Eric Vallabh Minikel and Daniel MacArthur, Broad Institute of MIT and Harvard


[Wang 2016]: http://www.ncbi.nlm.nih.gov/pubmed/27253448 "Wang Z, Sadovnick AD, Traboulsee AL, Ross JP, Bernales CQ, Encarnacion M, Yee  IM, de Lemos M, Greenwood T, Lee JD, Wright G, Ross CJ, Zhang S, Song W, Vilariño-Güell C. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron.  2016 Jun 1;90(5):948-54. doi: 10.1016/j.neuron.2016.04.039. PubMed PMID: 27253448."

[Richards 2015]: http://www.ncbi.nlm.nih.gov/pubmed/25741868/ "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants:  a joint consensus recommendation of the American College of Medical Genetics and  Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5. PubMed PMID: 25741868; PubMed Central PMCID: PMC4544753."

[MacArthur 2014]: http://www.ncbi.nlm.nih.gov/pubmed/24759409 "MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams  DR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, Valle D, Voight BF, Winckler W, Gunter C. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014 Apr 24;508(7497):469-76. doi: 10.1038/nature13127. PubMed PMID: 24759409; PubMed Central PMCID: PMC4180223."

[Sadovnick 1998]: http://www.ncbi.nlm.nih.gov/pubmed/9706723 "Sadovnick AD, Risch NJ, Ebers GC. Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group. Can J Neurol Sci. 1998 Aug;25(3):216-21. PubMed PMID: 9706723."

[Traboulsee 2014]: http://www.ncbi.nlm.nih.gov/pubmed/24770783 "Traboulsee AL, Bernales CQ, Ross JP, Lee JD, Sadovnick AD, Vilariño-Güell C. Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression. Neurogenetics. 2014 Aug;15(3):165-9. doi: 10.1007/s10048-014-0403-3. Epub 2014 Apr 26. PubMed PMID: 24770783."

[Kirov 2014]: http://www.ncbi.nlm.nih.gov/pubmed/23992924 "Kirov G, Rees E, Walters JT, Escott-Price V, Georgieva L, Richards AL, Chambert KD, Davies G, Legge SE, Moran JL, McCarroll SA, O'Donovan MC, Owen MJ. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry. 2014 Mar 1;75(5):378-85. doi: 10.1016/j.biopsych.2013.07.022. Epub 2013 Aug 28. PubMed PMID: 23992924; PubMed Central PMCID: PMC4229045."

[Minikel 2016]: http://www.ncbi.nlm.nih.gov/pubmed/26791950 "Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, McLean CY, Tung JY, Yu LP, Gambetti P, Blevins J, Zhang S, Cohen Y, Chen W, Yamada M, Hamaguchi T, Sanjo N, Mizusawa H, Nakamura Y, Kitamoto T, Collins SJ, Boyd A, Will RG, Knight R, Ponto C, Zerr I, Kraus TF, Eigenbrod S, Giese A, Calero M, de Pedro-Cuesta J, Haïk S, Laplanche JL, Bouaziz-Amar E, Brandel JP, Capellari S, Parchi P, Poleggi A, Ladogana A, O'Donnell-Luria AH, Karczewski KJ,  Marshall JL, Boehnke M, Laakso M, Mohlke KL, Kähler A, Chambert K, McCarroll S, Sullivan PF, Hultman CM, Purcell SM, Sklar P, van der Lee SJ, Rozemuller A, Jansen C, Hofman A, Kraaij R, van Rooij JG, Ikram MA, Uitterlinden AG, van Duijn  CM; Exome Aggregation Consortium (ExAC), Daly MJ, MacArthur DG. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016 Jan 20;8(322):322ra9. doi: 10.1126/scitranslmed.aad5169. PubMed PMID: 26791950; PubMed Central PMCID: PMC4774245."

[Alonso & Hernan 2008]: http://www.ncbi.nlm.nih.gov/pubmed/18606967 "Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008 Jul 8;71(2):129-35. doi: 10.1212/01.wnl.0000316802.35974.34. Review. PubMed PMID: 18606967; PubMed Central PMCID: PMC4109189."

[Do 2011]: http://www.ncbi.nlm.nih.gov/pubmed/21738487 "Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011 Jun;7(6):e1002141. doi: 10.1371/journal.pgen.1002141. Epub 2011 Jun 23. PubMed PMID: 21738487; PubMed Central PMCID: PMC3121750."

[Gilks 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15680457 "Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):415-6. PubMed PMID: 15680457."

[Kachergus 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15726496 "Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder  across European populations. Am J Hum Genet. 2005 Apr;76(4):672-80. Epub 2005 Feb 22. PubMed PMID: 15726496; PubMed Central PMCID: PMC1199304."

[Nichols 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15680455 "Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T; Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):410-2. PubMed PMID: 15680455."

[Di Fonzo 2005]: http://www.ncbi.nlm.nih.gov/pubmed/15680456 "Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent  LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005 Jan 29-Feb 4;365(9457):412-5. PubMed PMID: 15680456."

[Lesage 2006]: http://www.ncbi.nlm.nih.gov/pubmed/16436781 "Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006 Jan 26;354(4):422-3. PubMed PMID: 16436781."

[Ozelius 2006]: http://www.ncbi.nlm.nih.gov/pubmed/16436782 "Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N  Engl J Med. 2006 Jan 26;354(4):424-5. PubMed PMID: 16436782."

[Elbaz 2002]: http://www.ncbi.nlm.nih.gov/pubmed/11781119 "Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol. 2002 Jan;55(1):25-31. PubMed PMID: 11781119."

[Driver 2009]: http://www.ncbi.nlm.nih.gov/pubmed/19188574/ "Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009 Feb 3;72(5):432-8. doi: 10.1212/01.wnl.0000341769.50075.bb. PubMed PMID: 19188574; PubMed Central PMCID: PMC2676726."

[Goldwurm 2007]: http://www.ncbi.nlm.nih.gov/pubmed/17215492 "Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, Pezzoli G. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology. 2007 Apr 3;68(14):1141-3. Epub 2007 Jan 10. PubMed PMID: 17215492."

